{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:43:01Z","timestamp":1789342981826,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic Sclerosis (SSc) is a chronic autoimmune disease with a complex pathogenesis that includes vascular injury, abnormal immune activation, and tissue fibrosis. We provided a complete epidemiological characterization of SSc in the Tuscany region (Italy), considering prevalence and incidence, survival, comorbidities and drug prescriptions, by using a multi-database population-based approach. Cases of SSc diagnosed between 1st January 2003 and 31st December 2017 among residents in Tuscany were collected from the population-based Rare Diseases Registry of Tuscany. All cases were linked to regional health and demographic databases to obtain information about vital statistics, principal causes of hospitalization, complications and comorbidities, and drug prescriptions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of SSc in Tuscany population resulted to be 22.2 per 100,000, with the highest prevalence observed for the cases aged\u2009\u2265\u200965\u00a0years (33.2 per 100,000, CI 95% 29.6\u201337.3). In females, SSc was predominant (86.7% on the total) with an overall sex ratio F\/M of 6.5. Nevertheless, males presented a more severe disease, with a lower survival and significant differences in respiratory complications and metabolic comorbidities. Complications and comorbidities such as pulmonary involvement (HR\u2009=\u20091.66, CI 95% 1.17\u20132.35), congestive heart failure (HR\u2009=\u20092.76, CI 95% 1.80\u20134.25), subarachnoid and intracerebral haemorrhage (HR\u2009=\u20092.33, CI 95% 1.21\u20134.48) and malignant neoplasms (HR\u2009=\u20091.63, CI 95% 1.06\u20132.52), were significantly associated to a lower survival, also after adjustment for age, sex and other SSc-related complications. Disease-modifying antirheumatic drugs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors were the drugs with the more increasing prevalence of use in the 2008\u20132017 period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The multi-database approach is important in the investigation of rare diseases where it is often difficult to provide accurate epidemiological indicators. A population-based registry can be exploited in synergy with health databases, to provide evidence related to disease outcomes and therapies and to assess the burden of disease, relying on a large cohort of cases. Building an integrated archive of data from multiple databases linking a cohort of patients to their comorbidities, clinical outcomes and survival, is important both in terms of treatment and prevention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01733-4","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T08:19:57Z","timestamp":1613636397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy)"],"prefix":"10.1186","volume":"16","author":[{"name":"the Rare Diseases Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-3144","authenticated-orcid":false,"given":"Alessio","family":"Coi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Barsotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Almerigogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Prediletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Selvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Gaetano","family":"Tavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"3","key":"1733_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M. Kuwana N Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017;2(3):137\u201352. https:\/\/doi.org\/10.5301\/jsrd.5000249.","journal-title":"J Scleroderma Relat Disord"},{"issue":"4","key":"1733_CR2","first-page":"3","volume":"37 Suppl 119","author":"S Barsotti","year":"2019","unstructured":"Barsotti S, Orlandi M, Codullo V, Di Battista M, Lepri G, Della Rossa A, Guiducci S. One year in review 2019: systemic sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 119(4):3\u201314.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1733_CR3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE, Farge-Bancel D, Allanore Y, M\u00fcller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kum\u00e1novics G, Coleiro B, Feierl E, Szucs G, Von M\u00fchlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, K\u00f6tter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1733_CR4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/1756-185X.13716","volume":"22","author":"L Zhong","year":"2019","unstructured":"Zhong L, Pope M, Shen Y, Hernandez JJ, Wu L. Prevalence and incidence of systemic sclerosis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(12):2096\u2013107.","journal-title":"Int J Rheum Dis"},{"key":"1733_CR5","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","volume":"9","author":"B Ranque","year":"2010","unstructured":"Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9:A311\u20138.","journal-title":"Autoimmun Rev"},{"key":"1733_CR6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/ard.2008.091348","volume":"68","author":"UA Walker","year":"2009","unstructured":"Walker UA, Tyndall A. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (Eustar) group database. Ann Rheum Dis. 2009;68:856\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1733_CR7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.semarthrit.2004.09.001","volume":"34","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA, Drosos AA. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum. 2005;34(5):714\u201320.","journal-title":"Semin Arthritis Rheum"},{"key":"1733_CR8","first-page":"878","volume":"25","author":"P Air\u00f2","year":"2007","unstructured":"Air\u00f2 P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M. Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol. 2007;25:878\u201380.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1733_CR9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MD.0b013e318189372f","volume":"87","author":"MC Arias-Nu\u00f1ez","year":"2008","unstructured":"Arias-Nu\u00f1ez MC, Llorca J, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J, Gonzalez-Juanatey C, Gonzalez-Gay MA. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore). 2008;87(5):272\u201380.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"1733_CR10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2012-202007","volume":"72","author":"A Man","year":"2013","unstructured":"Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, Simms RW, Choi HK. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72(7):1188\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1733_CR11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5114\/reum.2017.69776","volume":"55","author":"S Shenavandeh","year":"2017","unstructured":"Shenavandeh S, Naseri R. Assessment of hospitalization and mortality of scleroderma in-patients: a thirteen-year study. Reumatologia. 2017;55(4):163\u20138.","journal-title":"Reumatologia"},{"key":"1733_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14376","author":"S Abbot","year":"2019","unstructured":"Abbot S, McWilliams L, Spargo L, de Costa C, Ur-Rehman Z, Proudman S, Bossingham D. Scleroderma in Cairns: an epidemiological study. Intern Med J. 2019. https:\/\/doi.org\/10.1111\/imj.14376.","journal-title":"Intern Med J"},{"issue":"4","key":"1733_CR13","first-page":"68","volume":"36 Suppl 113","author":"PE Carreira","year":"2018","unstructured":"Carreira PE, Carmona L, Joven BE, Loza E, Andreu JL, Riemekasten G, Vettori S, Balbir-Gurman A, Air\u00f2 P, Walker UA, Damjanov N, Matucci-Cerinic M, Ananieva LP, Rednic S, Czirj\u00e1k L, Distler O, Farge D, Hesselstrand R, Corrado A, Caramaschi P, Tikly M, Allanore Y, the EUSTAR co-authors. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clin Exp Rheumatol. 2018;36 Suppl 113(4):68\u201375.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1733_CR14","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/kez558","volume":"59","author":"C Mihai","year":"2019","unstructured":"Mihai C, Distler O, Gheorghiu AM, Constantin PI, Dobrota R, Jordan S, Smith V, Hachulla E, Henes J, Siegert E, Vettori S, M\u00fcller-Ladner U, Matucci Cerinic M, Allanore Y, EUSTAR. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology (Oxford). 2019;59(8):2016\u201323.","journal-title":"Rheumatology (Oxford)"},{"key":"1733_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.11.005","author":"M Noviani","year":"2019","unstructured":"Noviani M, Saffari SE, Tan JL, Yip JWL, Teng GG, Law WG, Chan GYL, Santosa A, Lim AYN, Hong C, Ng SA, Tay ELW, Ruan W, Yap J, Low AHL. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. Semin Arthritis Rheum. 2019. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.005.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1733_CR16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","volume":"21","author":"MR Pokeerbux","year":"2019","unstructured":"Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC, Allanore Y, Jego P, Bienvenu B, Berthier S, Mekinian A, Hachulla E, Launay D. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019;21(1):86.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1733_CR17","first-page":"e2628","volume":"10","author":"O Amoda","year":"2018","unstructured":"Amoda O, Ravat V, Datta S, Saroha B, Patel RS. Trends in demographics, hospitalization outcomes, comorbidities, and mortality risk among systemic sclerosis patients. Cureus. 2018;10(5):e2628.","journal-title":"Cureus"},{"key":"1733_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41927-018-0043-6","volume":"2","author":"SA Butt","year":"2018","unstructured":"Butt SA, Jeppesen JL, Fuchs C, Mogensen M, Engelhart M, Torp-Pedersen C, Gislason GH, Jacobsen S, Andersson C. Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatol. 2018;2:36\u201346.","journal-title":"BMC Rheumatol"},{"issue":"8","key":"1733_CR19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/ijerph15081644","volume":"15","author":"Y Kodra","year":"2018","unstructured":"Kodra Y, Weinbach J, Posada-de-la-Paz M, Coi A, Lemonnier SL, van Enckevort D, Roos M, Jacobsen A, Cornet R, Ahmed SF, Bros-Facer V, Popa V, Van Meel M, Renault D, von Gizycki R, Santoro M, Landais P, Torreri P, Carta C, Mascalzoni D, Gainotti S, Lopez E, Ambrosini A, M\u00fcller H, Reis R, Bianchi F, Rubinstein YR, Lochm\u00fcller H, Taruscio D. Recommendations for improving the quality of rare disease registries. Int J Environ Res Public Health. 2018;15(8):1644.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"1733_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000369993","volume":"18","author":"M Santoro","year":"2015","unstructured":"Santoro M, Coi A, Lipucci Di Paola M, Bianucci AM, Gainotti S, Mollo E, Taruscio D, Vittozzi L, Bianchi F. Rare disease registries classification and characterization: a data mining approach. Public Health Genomics. 2015;18(2):113\u201322.","journal-title":"Public Health Genomics"},{"key":"1733_CR21","unstructured":"Rare Diseases Registry of Tuscany. http:\/\/malattierare.toscana.it."},{"key":"1733_CR22","unstructured":"Taruscio D (ed) Il Registro Nazionale e i Registri Regionali\/interregionali delle malattie rare. Rapporto anno 2011. Roma: Istituto Superiore di Sanit\u00e0; 2011 (Rapporti ISTISAN 11\/20)."},{"key":"1733_CR23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1733_CR24","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, M\u00fcller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"1733_CR25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.12968\/hmed.2019.80.9.530","volume":"80","author":"M Hughes","year":"2019","unstructured":"Hughes M, Herrick AL. Systemic Sclerosis. Br J Hosp Med. 2019;80:530\u20136.","journal-title":"Br J Hosp Med"},{"key":"1733_CR26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0749-0704(02)00023-4","volume":"18","author":"M Cossio","year":"2002","unstructured":"Cossio M, Menon Y, Wilson W, deBoisblanc BP. Life-threatening complications of systemic sclerosis. Crit Care Clin. 2002;18:819\u201339.","journal-title":"Crit Care Clin"},{"issue":"5","key":"1733_CR27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/ard.2008.095299","volume":"68","author":"J Avouac","year":"2009","unstructured":"Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S. Miniati i, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, F\u00f6ldvari I, Furst DE, M\u00fcller-Ladner U, Seibold J, Silver RM, Takehara K, Garay Toth B, Tyndall A, G Valentini, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, EUSTAR Coauthors European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2009;68(5):629\u201334.","journal-title":"Ann Rheum Dis"},{"key":"1733_CR28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, M\u00fcller-Ladner U, EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1733_CR29","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70(11):1820\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"1733_CR30","volume-title":"Stata Statistical Software: release 16","author":"StataCorp","year":"2019","unstructured":"StataCorp. Stata Statistical Software: release 16. College Station: StataCorp LLC; 2019."},{"key":"1733_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa782","author":"F Motta","year":"2020","unstructured":"Motta F, Codullo V, Ramoni V, Cesari S, Ferrario G, Fiandrino G, Beneventi F, Rampello S, Johnsson H, Montecucco C, Graham GJ. Role of placental inflammatory mediators and growth factors in patients with rheumatic diseases with a focus on systemic sclerosis. Rheumatology (Oxford). 2020. https:\/\/doi.org\/10.1093\/rheumatology\/keaa782.","journal-title":"Rheumatology (Oxford)"},{"key":"1733_CR32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S191418","volume":"11","author":"A Bergamasco","year":"2019","unstructured":"Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019;11:257\u201373.","journal-title":"Clin Epidemiol"},{"issue":"11","key":"1733_CR33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.amjmed.2013.06.025","volume":"126","author":"SY Chu","year":"2013","unstructured":"Chu SY, Chen YJ, Liu CJ, Tseng WC, Lin MW, Hwang CY, Chen CC, Lee DD, Chen TJ, Chang YT, Wang WJ, Liu HN. Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Am J Med. 2013;126(11):982\u20138.","journal-title":"Am J Med"},{"issue":"3","key":"1733_CR34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.amjmed.2015.10.037","volume":"129","author":"JA Avi\u00f1a-Zubieta","year":"2016","unstructured":"Avi\u00f1a-Zubieta JA, Man A, Yurkovich M, Huang K, Sayre EC, Choi HK. Early cardiovascular disease after the diagnosis of systemic sclerosis. Am J Med. 2016;129(3):324\u201331.","journal-title":"Am J Med"},{"key":"1733_CR35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1445-5994.2007.01370.x","volume":"37","author":"SM Proudman","year":"2007","unstructured":"Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J. 2007;37:485\u201394.","journal-title":"Intern Med J"},{"issue":"9","key":"1733_CR36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00296-019-04371-z","volume":"39","author":"E Pagkopoulou","year":"2019","unstructured":"Pagkopoulou E, Arvanitaki A, Daoussis D, Garyfallos A, Kitas G, Dimitroulas T. Comorbidity burden in systemic sclerosis: beyond disease-specific complications. Rheumatol Int. 2019;39(9):1507\u201317.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1733_CR37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.2006.066340","volume":"67","author":"L Czirj\u00e1k","year":"2008","unstructured":"Czirj\u00e1k L, Kum\u00e1novics G, Varj\u00fa C, Nagy Z, P\u00e1kozdi A, Szekanecz Z, Szucs G. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):59\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1733_CR38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4330\/wjc.v6.i9.993","volume":"6","author":"S Lambova","year":"2014","unstructured":"Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol. 2014;6(9):993\u20131005.","journal-title":"World J Cardiol"},{"issue":"10","key":"1733_CR39","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3899\/jrheum.131547","volume":"41","author":"C Mecoli","year":"2014","unstructured":"Mecoli C, Purohit S, Sandorfi N, Derk CT. Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. J Rheumatol. 2014;41(10):2049\u201354.","journal-title":"J Rheumatol"},{"key":"1733_CR40","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VC Steen","year":"1998","unstructured":"Steen VC, Medsger TA. Case control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41:1613\u20139.","journal-title":"Arthritis Rheum"},{"key":"1733_CR41","doi-asserted-by":"crossref","first-page":"102403","DOI":"10.1016\/j.autrev.2019.102403","volume":"18","author":"J Blagojevic","year":"2019","unstructured":"Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L. Is there today a place for corticosteroids in the treatment of scleroderma? Autoimmun Rev. 2019;18:102403.","journal-title":"Autoimmun Rev"},{"key":"1733_CR42","first-page":"126","volume":"32","author":"TP Angelopoulos","year":"2014","unstructured":"Angelopoulos TP, Tentolouris NK, Bertsias GK, Boumpas DT. Steroid-induced diabetes in rheumatologic patients. Clin Exp Rheumatol. 2014;32:126\u201330.","journal-title":"Clin Exp Rheumatol"},{"key":"1733_CR43","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth M, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655\u201366.","journal-title":"N Engl J Med"},{"key":"1733_CR44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II), a double-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2016;4:708\u201319.","journal-title":"Lancet Respir Med"},{"key":"1733_CR45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","volume":"33","author":"C Denton","year":"1994","unstructured":"Denton C, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin-A: report of three cases. Rheumatology. 1994;33:90\u20132.","journal-title":"Rheumatology"},{"issue":"1","key":"1733_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13075-020-2140-3","volume":"22","author":"S Panopoulos","year":"2020","unstructured":"Panopoulos S, Chatzidionysiou \u039a, Tektonidou MG, et al. Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Res Ther. 2020;22(1):56. https:\/\/doi.org\/10.1186\/s13075-020-2140-3.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1733_CR47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jbspin.2016.10.002","volume":"84","author":"C Bruni","year":"2017","unstructured":"Bruni C, Praino E, Guiducci S, Bellando-Randone S, Furst DE, Matucci-Cerinic M. Hydroxychloroquine and joint involvement in systemic sclerosis: preliminary beneficial results from a retrospective case-control series of an EUSTAR Center. Joint Bone Spine. 2017;84(6):747\u20138.","journal-title":"Joint Bone Spine"},{"key":"1733_CR48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut M, Launay D, Rivi\u00e8re S, Mah\u00e9vas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17:582\u20137.","journal-title":"Autoimmun Rev"},{"key":"1733_CR49","doi-asserted-by":"crossref","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellv\u00ed I, Air\u00f3 P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, L\u00f3pez-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78:979\u2013987.","DOI":"10.1136\/annrheumdis-2018-214816"},{"key":"1733_CR50","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"key":"1733_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","volume":"199","author":"JP Gomes","year":"2019","unstructured":"Gomes JP, Santos L, Shoenfeld Y. Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis. Clin Immunol. 2019;199:25\u20138. https:\/\/doi.org\/10.1016\/j.clim.2018.12.006.","journal-title":"Clin Immunol"},{"key":"1733_CR52","first-page":"27","volume":"39","author":"J Blagojevic","year":"2020","unstructured":"Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, L\u00f3r\u00e1nd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirj\u00e1k L, Denton CP, Distler O, Allanore Y, M\u00fcller-Ladner U, Moggi-Pignone A, Matucci-Cerinic M, Del Galdo F, EUSTAR co-workers. Use of vasoactive\/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. ClinRheumatol. 2020;39:27\u201336.","journal-title":"ClinRheumatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01733-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:43:02Z","timestamp":1613695382000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01733-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01733-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tuscany Region requests the delivery of an Informative Note to each patient (document available at: ) prior to their inclusion in the Rare Diseases Registry of Tuscany, according to Article 13 of Privacy Code (Legislative Decree 196\/2003 Privacy Code). The Informative Note specifies that data of patients can be used for research and surveillance aims. Co-authors performing the study cannot in any way get the identity of patients and only aggregated results are published. All procedures performed in this study were in accordance with the Ethical Standards of the Ethical Committee of Azienda Ospedaliero-Universitaria Pisana (the publication of the study was approved on the 27th October 2020).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}